Next Article in Journal
Ellagitannins in Cancer Chemoprevention and Therapy
Previous Article in Journal
Monoclonal IgA Antibodies for Aflatoxin Immunoassays
Article Menu
Issue 5 (May) cover image

Export Article

Comment published on 27 October 2016, see Toxins 2016, 8(11), 311.

Open AccessArticle
Toxins 2016, 8(5), 149; doi:10.3390/toxins8050149

Determination of Asymmetric and Symmetric Dimethylarginine in Serum from Patients with Chronic Kidney Disease: UPLC-MS/MS versus ELISA

1
Department of Organic Chemistry, Separation Science Group, Ghent University, Krijgslaan 281, S4-bis, B-9000 Ghent, Belgium
2
Department of Internal Medicine, Nephrology Section, Ghent University Hospital, De Pintelaan 185, B-9000 Ghent, Belgium
*
Author to whom correspondence should be addressed.
Academic Editor: Joachim Jankowski
Received: 21 January 2016 / Revised: 19 April 2016 / Accepted: 4 May 2016 / Published: 13 May 2016
View Full-Text   |   Download PDF [1648 KB, uploaded 13 May 2016]   |  

Abstract

Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide (NO) synthesis, and its structural isomer symmetric dimethylarginine (SDMA) are uremic toxins accumulating in chronic kidney disease (CKD) patients. The objective of this study was to develop and validate a robust UPLC-MS/MS method for the simultaneous determination of ADMA and SDMA in human serum. Chromatographic separation after butyl ester derivatization was achieved on an Acquity UPLC BEH C18 column, followed by tandem mass spectrometric detection. After validation, the applicability of the method was evaluated by the analysis of serum samples from 10 healthy controls and 77 CKD patients on hemodialysis (CKD5HD). Both ADMA (0.84 ± 0.19 µM vs. 0.52 ± 0.07 µM) and SDMA concentrations (2.06 ± 0.82 µM vs. 0.59 ± 0.13 µM) were significantly (p < 0.001) elevated in CKD5HD patients compared to healthy controls. In general, low degrees of protein binding were found for both ADMA and SDMA. In addition, an established commercially available ELISA kit was utilized on the same samples (n = 87) to compare values obtained both with ELISA and UPLC-MS/MS. Regression analysis between these two methods was significant (p < 0.0001) but moderate for both ADMA (R = 0.78) and SDMA (R = 0.72). View Full-Text
Keywords: asymmetric dimethylarginine; symmetric dimethylarginine; UPLC-MS/MS; ELISA; chronic kidney disease asymmetric dimethylarginine; symmetric dimethylarginine; UPLC-MS/MS; ELISA; chronic kidney disease
Figures

Figure 1a

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Boelaert, J.; Schepers, E.; Glorieux, G.; Eloot, S.; Vanholder, R.; Lynen, F. Determination of Asymmetric and Symmetric Dimethylarginine in Serum from Patients with Chronic Kidney Disease: UPLC-MS/MS versus ELISA. Toxins 2016, 8, 149.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top